Open To Enhance Manufacturing Footprint In US: Sun Pharma
Richard Ascroft, the company's chief executive officer for the North America business, stated that the Mumbai-based drug maker already has a manufacturing footprint in the US.
Drug major Sun Pharmaceutical Industries Ltd. on Wednesday said it is open to enhancing its manufacturing footprint in the US amid the Trump administration imposing a 100% tariff on branded and patented medicines.
In an analyst call, Richard Ascroft, the company's chief executive officer for the North America business, stated that the Mumbai-based drug maker already has a manufacturing footprint in the US.
"We are kind of constantly assessing that manufacturing footprint, and we are open to considering this in the US in due time," he said, when asked if the drug maker is open to localised manufacturing in the US in the wake of high tariffs.
The company is open for all options, he said without sharing any details.
Ascroft noted that the tariff situation remains 'very fluid and uncertain', and it is hard for the company to determine the impact it could have on its generics or innovative medicines portfolio at this time.
Sun Pharma Executive Chairman Dilip Shanghvi said the company remains on track to launch UNLOXCYT, an FDA-approved treatment for advanced skin cancer, in the US in the second half of fiscal 2026.
The company is also planning to file ILUMYA psoriatic arthritis SPLA during the second half of financial year 2026, he added.
The company continues to invest in building a research and development pipeline of its innovative medicines business, Shanghvi stated.
